Table 1 Baseline patient and tumor characteristics according to EVI1 expression
From: EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Parameter | Category | EVI1-low (≤ 112.16) N = 497 N (%) | EVI1-high (≥ 112.17) N = 496 N (%) | Overall N = 993 N | p-value |
|---|---|---|---|---|---|
Age, years | 993 | ||||
≤ 50 | 268 (49.7%) | 271 (50.3%) | 539 | 0.849 | |
> 50 | 229 (50.4%) | 225 (49.6%) | 454 | ||
median (range) | 49.0 (23–80) | 49.0 (24–74) | 49.0 (23–80) | 0.723 | |
Tumor size | 990 | ||||
cT1-2 | 321 (46.6%) | 368 (53.4%) | 689 | 0.002 | |
cT3-4a-d | 173 (57.5%) | 128 (42.5%) | 301 | ||
missing | 3 | 0 | 3 | ||
Nodal status | 976 | ||||
cN-negative | 219 (50.3%) | 216 (49.7%) | 435 | 0.949 | |
cN-positive | 271 (50.1%) | 270 (49.9%) | 541 | ||
missing | 7 | 10 | 17 | ||
Tumor grade | 943 | ||||
G1-2 | 299 (51.7%) | 279 (48.3%) | 578 | 0.423 | |
G3 | 179 (49.0%) | 186 (51.0%) | 365 | ||
missing | 19 | 31 | 50 | ||
Histological type | 993 | ||||
Ductal invasive | 449 (50.4%) | 441 (49.6%) | 890 | 0.468 | |
Non-ductal | 48 (46.6%) | 55 (53.4%) | 103 | ||
BC subtype | 882 | ||||
HR + /HER2- | 213 (47.5%) | 235 (52.5%) | 448 | 0.435 | |
HR + /HER2 + | 73 (55.3%) | 59 (44.7%) | 132 | ||
HR-/HER2 + | 42 (48.8%) | 44 (51.2%) | 86 | ||
TNBC | 102 (47.2%) | 114 (52.8%) | 216 | ||
missing | 67 | 44 | 111 | ||
Stromal TILs (N = 523) | Median (range) | 20.0 (0.0–90.0) | 20.0 (0.0–100.0) | 20.0 (0.0–100.0) | 0.848 |
missing | 253 | 217 | 470 | ||
Ki-67% (N = 770) | Median (range) | 28.5 (0.5–99.0) | 27.5 (0.0–100.0) | 28.0 (0.0–100.0) | 0.862 |
missing | 94 | 129 | 223 |